Olivo Alicia C 4

Accession 0001628280-25-054270

CIK 0001077183other

View on SEC.gov Company Profile

Filed

Nov 27, 7:00 PM ET

Accepted

Nov 28, 4:18 PM ET

Size

29.2 KB

Accession

0001628280-25-054270

Insider Transaction Report

Form 4

Period: 2025-11-25

NEOGENOMICS INCNEO

Olivo Alicia C

EVP, GC & Business Development

Transactions

Exercise/Conversion
Common Stock
2025-11-25$10.05/sh+8,977$90,219→ 51,999 total
Sale
Common Stock
2025-11-25$12.00/sh−20,916$250,992→ 31,083 total
Exercise/Conversion
Stock Option (Right to Buy)
2025-11-25−8,977→ 46,355 total
Exercise: $10.05Exp: 2029-09-01→ Common Stock (8,977 underlying)

Holdings

Stock Option (Right to Buy)
Exercise: $19.12Exp: 2026-09-30→ Common Stock (1,046 underlying)
1,046
Stock Option (Right to Buy)
Exercise: $27.34Exp: 2027-05-01→ Common Stock (1,024 underlying)
1,024
Stock Option (Right to Buy)
Exercise: $48.99Exp: 2028-05-01→ Common Stock (516 underlying)
516
Stock Option (Right to Buy)
Exercise: $46.10Exp: 2028-08-01→ Common Stock (1,117 underlying)
1,117
Stock Option (Right to Buy)
Exercise: $9.45Exp: 2029-05-01→ Common Stock (22,222 underlying)
22,222
Stock Option (Right to Buy)
Exercise: $19.65Exp: 2030-05-11→ Common Stock (36,508 underlying)
36,508
Restricted Stock Unit
Exercise: $0.00→ Common Stock (6,503 underlying)
6,503
Performance Stock Unit
Exercise: $0.00From: 2026-05-11→ Common Stock (19,508 underlying)
19,508
Stock Option (Right to Buy)
Exercise: $16.45Exp: 2034-02-23→ Common Stock (42,344 underlying)
42,344
Restricted Stock Unit
Exercise: $0.00From: 2026-01-13→ Common Stock (59,382 underlying)
59,382
Performance Stock Unit
Exercise: $0.00From: 2027-02-23→ Common Stock (25,330 underlying)
25,330
Restricted Stock Unit
Exercise: $0.00→ Common Stock (16,886 underlying)
16,886
Stock Option (Right to Buy)
Exercise: $13.05Exp: 2035-02-21→ Common Stock (107,450 underlying)
107,450
Restricted Stock Unit
Exercise: $0.00→ Common Stock (63,238 underlying)
63,238

Footnotes (17)

[F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
[F10]Once vested, the shares of common stock are not subject to expiration.
[F11]On May 11, 2023, Ms. Olivo was granted 19,508 performance stock units representing the number of shares that may vest at target performance. The maximum number of shares that may vest pursuant to the performance criteria is29,262. The number of performance stock units that may vest is based on the achievement of certain share growth goals based on the weighted average price of the Company's common stock over the 20-day trailing trading period at theapplicable measurement dates, subject to continued service with the Company.
[F12]On February 23, 2024, Ms. Olivo was granted 42,344 stock options. The options vest ratably over the first three anniversary dates of the grant date.
[F13]On February 23, 2024, Ms. Olivo was granted 25,330 performance stock units representing the number of shares that may vest at target performance. The maximum number of shares that may vest pursuant to the performance criteria is37,996. 50% of the number of performance stock units that may vest is based on the achievement of certain share growth goals based on the weighted average price of the Company's common stock over the 20-day trailing trading period atthe applicable measurement dates, subject to continued service with the Company. 50% of the number of performance stock units that may vest is based on the achievement of certain revenue growth goals based on the achievement of thecumulative fiscal year revenue goal at the applicable measurement amounts, subject to continued service with the Company.
[F14]On February 23, 2024, Ms. Olivo was granted 25,329 restricted stock units. The restricted stock units vest ratably over the first three anniversary dates of the grant date.
[F15]This stock option was granted as a premium-price stock option. To calculate the premium exercise price we used the closing price on February 20, 2025 and multiplied by 110%.
[F16]On February 21, 2025, Ms. Olivo was granted 107,450 stock options. The options vest ratably over the first three anniversary dates of the grant date.
[F17]On February 21, 2025, Ms. Olivo was granted 63,238 restricted stock units. The restricted stock units vest ratably over the first three anniversary dates of the grant date.
[F2]On September 1, 2022, Ms. Olivo was granted 55,332 stock options. The options vest ratably over the first four anniversary dates of the grant date.
[F3]On September 30, 2019, Ms. Olivo was granted 1,394 stock options. The options vest ratably over the first four anniversary dates of the grant date.
[F4]On May 1, 2020, Ms. Olivo was granted 1,024 stock options. The options vest ratably over the first four anniversary dates of the grant date.
[F5]On May 1, 2021, Ms. Olivo was granted 516 stock options. The options vest ratably over the first four anniversary dates of the grant date.
[F6]On August 1, 2021, Ms. Olivo was granted 1,117 stock options. The options vest ratably over the first four anniversary dates of the grant date.
[F7]On May 1, 2022, Ms. Olivo was granted 22,222 stock options. The options vest ratably over the first four anniversary dates of the grant date.
[F8]On May 11, 2023, Ms. Olivo was granted 36,508 stock options. The options vest ratably over the first three anniversary dates of the grant date.
[F9]On May 11, 2023, Ms. Olivo was granted 19,508 restricted stock units. The restricted stock units vest ratably over the first three anniversary dates of the grant date.

Documents

1 file

4
wk-form4_1764364698.xmlPrimary
FORM 4

Issuer

NEOGENOMICS INC

CIK 0001077183

→

Entity typeother

Related Parties

filerCIK 0001951869

Filing Metadata

Form type: 4
Filed: Nov 27, 7:00 PM ET
Accepted: Nov 28, 4:18 PM ET
Size: 29.2 KB

View on SEC.gov